TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos†or the "Company†), a clinical-stage biotechnology company developing life- improving medicines to treat degenerative muscle diseases, today announced its financial results for the third quarter ended September 30, 2025, and other corporate and clinical updates. "The second half of 2025 represents another important milestone for Satellos as we advance toward initiating the global Phase 2 pediatric study of SA. ...